(Albany, US) DelveInsight has launched a new report on “Meningioma Market Insights, Epidemiology, and Market Forecast-2030”.

 

DelveInsight’s “Meningioma Market Insights, Epidemiology, and Market Forecast-2030” report delivers an in-depth understanding of the Meningioma , historical and forecasted epidemiology as well as the Meningioma market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.

 

Some of the facts:

• As per DelveInsight, Increasing trend could be artefactual and could be the result of an aging population, improvement in health access and diagnostic procedures, changes in coding classification for tumors recorded in registries, and/or an increase in the rate of histological confirmation, even in the elderly.
• Even if comparisons are made difficult due to differences in methodologies, available annual incidence rates (sex- and age-standardized, generally on the US or World standard population), provided by population-based registries range from 1.3/100,000 to 7.8/100,000 for cerebral meningiomas.
• Atypical and malignant meningiomas comprise a small fraction of the total (~5%) and have a slight male predominance. Reported rates for Black Non-Hispanics are slightly higher (6.67) than for White Non-Hispanic and Hispanics (5.90 and 5.94, respectively).

 

Request for free sample report: https://www.delveinsight.com/sample-request/meningioma-market

 

Scope of the Report:

• The report covers the descriptive overview of Meningioma , explaining its causes, signs and symptoms, pathophysiology, diagnosis and currently available therapies
• Comprehensive insight has been provided into the Meningioma epidemiology and treatment in the 7MM
• Additionally, an all-inclusive account of both the current and emerging therapies for Meningioma are provided, along with the assessment of new therapies, which will have an impact on the current treatment landscape
• A detailed review of Meningioma market; historical and forecasted is included in the report, covering drug outreach in the 7MM
• The report provides an edge while developing business strategies, by understanding trends shaping and driving the global Meningioma market

 

Meningiomas are the most common benign intracranial tumor. They originate from arachnoid cap cells, which are cells within the thin, spiderweb-like membrane that covers the brain and spinal cord. The arachnoid is one of three protective layers, collectively known as the meninges, which surround the brain and the spinal cord. The other two layers of the meninges are the dura mater and pia mater. Although the majority of meningiomas are benign, these tumors can grow slowly until they are very large, if left undiscovered, and, in some locations, can be severely disabling and life-threatening. Other forms of meningioma may be more aggressive. Most patients develop a single meningioma; however, some patients may develop several tumors growing simultaneously in other locations of the brain or spinal cord.

Often, meningiomas cause no symptoms and require no immediate treatment. But the growth of benign meningiomas can cause serious problems. In some cases, such growth can be fatal. Some meningiomas are classified as atypical. These are not considered either benign or malignant (cancerous). But they may become malignant. A small number of meningiomas are cancerous. They tend to grow quickly. They also can spread to other parts of the brain and beyond, often to the lungs.

Risk factors for a meningioma include radiation treatment, female hormones, an inherited nervous system disorder, or obesity.

The WHO classification of brain tumors is the most widely utilized tool in grading tumor types. The WHO classification scheme recognizes 15 variations of meningiomas according to their cell type as seen under a microscope. These variations are called meningioma subtypes – the technical term for these cell variations is histological subtypes. These histological subtypes are organized into three grades that generally reflects the rate of growth and the likelihood of recurrence based on cytological features.

Atypical meningiomas (WHO grade II, which account for 18% of meningioma cases) exhibit increased tissue and cell abnormalities. These tumors grow at a faster rate than benign meningiomas and are often characterized by brain invasion. Atypical meningiomas have a higher likelihood of recurrence than benign meningiomas (WHO grade I).

Malignant meningiomas (WHO grade III) show increased cellular abnormalities and grow at a faster rate than benign and atypical meningiomas. Malignant meningiomas are the most likely to invade the brain and recur more frequently than the other two subtypes.

It can be difficult to diagnose meningiomas for several reasons. Because the majority of meningiomas are slow-growing tumors and primarily affect adults, symptoms may be so subtle that the patient and/or doctor may attribute them to the normal signs of aging. Adding to the confusion is that some of the symptoms associated with meningiomas can also be due to other medical conditions. Misdiagnosis is not uncommon and, may take several years for correct diagnosis.

 

Request for free sample report: https://www.delveinsight.com/sample-request/meningioma-market

 

Some of the companies are:

• Ariad Pharmaceutics
• Clarity Pharmaceuticals
• Actuate Therapeutics
• Abbvie
• And Many Others

Drugs covered:

• Brigatinib
• SARTATE
• 9-ING-41
• Veliparib
• And Many Others

 

Request for free sample report: https://www.delveinsight.com/sample-request/meningioma-market

 

Table of Contents:

1. Key Insights

2. Executive Summary of Meningioma

3. Competitive Intelligence Analysis for Meningioma

4. Meningioma : Market Overview at a Glance

4.1. Meningioma Total Market Share (%) Distribution in 2017

4.2. Meningioma Total Market Share (%) Distribution in 2030

5. Meningioma : Disease Background and Overview

5.1. Introduction

5.2. Sign and Symptoms 

5.3. Pathophysiology 

5.4. Risk Factors 

5.5. Diagnosis 

6. Patient Journey

7. Meningioma Epidemiology and Patient Population

7.1. Epidemiology Key Findings

7.2. Assumptions and Rationale: 7MM

7.3. Epidemiology Scenario: 7MM

7.3.1. Meningioma Epidemiology Scenario in the 7MM (2017-2030)

7.4. United States Epidemiology

7.4.1. Meningioma Epidemiology Scenario in the United States (2017-2030)

7.5. EU-5 Country-wise Epidemiology

7.5.1. Germany Epidemiology

7.5.1.1. Meningioma Epidemiology Scenario in Germany (2017-2030)

7.5.2. France Epidemiology

7.5.2.1. Meningioma Epidemiology Scenario in France (2017-2030)

7.5.3. Italy Epidemiology

7.5.3.1. Meningioma Epidemiology Scenario in Italy (2017-2030)

7.5.4. Spain Epidemiology

7.5.4.1. Meningioma Epidemiology Scenario in Spain (2017-2030)

7.5.5. United Kingdom Epidemiology

7.5.5.1. Meningioma Epidemiology Scenario in the United Kingdom (2017-2030)

7.5.6. Japan Epidemiology

7.5.6.1. Meningioma Epidemiology Scenario in Japan (2017-2030)

8. Treatment Algorithm, Current Treatment, and Medical Practices

8.1. Meningioma Treatment and Management

8.2. Meningioma Treatment Algorithm 

9. Unmet Needs

10. Key Endpoints of Meningioma Treatment

11. Marketed Products

11.1. List of Marketed Products in the 7MM

11.2. Drug Name: Company Name

11.2.1. Product Description

11.2.2. Regulatory Milestones

11.2.3. Other Developmental Activities

11.2.4. Pivotal Clinical Trials

11.2.5. Summary of Pivotal Clinical Trial

List to be continued in report

12. Emerging Therapies

12.1. Key Cross

12.2. Drug Name: Company Name

12.2.1. Product Description

12.2.2. Other Developmental Activities

12.2.3. Clinical Development

12.2.4. Safety and Efficacy

12.2.5. Product Profile

List to be continued in report

13. Meningioma : Seven Major Market Analysis

13.1. Key Findings

13.2. Meningioma Market Size in 7MM

13.3. Meningioma Market Size by Therapies in the 7MM

14. Attribute analysis

15. 7MM: Market Outlook

15.1. United States: Market Size

15.1.1. Meningioma Total Market Size in the United States

15.1.2. Meningioma Market Size by Therapies in the United States

15.2. EU-5 countries: Market Size and Outlook

15.3. Germany Market Size

15.3.1. Meningioma Total Market Size in Germany

15.3.2. Meningioma Market Size by Therapies in Germany

15.4. France Market Size

15.4.1. Meningioma Total Market Size in France

15.4.2. Meningioma Market Size by Therapies in France

15.5. Italy Market Size

15.5.1. Meningioma Total Market Size in Italy

15.5.2. Meningioma Market Size by Therapies in Italy

15.6. Spain Market Size

15.6.1. Meningioma Total Market Size in Spain

15.6.2. Meningioma Market Size by Therapies in Spain

15.7. United Kingdom Market Size

15.7.1. Meningioma Total Market Size in the United Kingdom

15.7.2. Meningioma Market Size by Therapies in the United Kingdom

15.8. Japan Market Outlook

15.8.1. Japan Market Size

15.8.2. Meningioma Total Market Size in Japan

15.8.3. Meningioma Market Size by Therapies in Japan

16. Access and Reimbursement Overview of Meningioma

17. KOL Views

18. Market Drivers

19. Market Barriers

20. Appendix

20.1. Bibliography

20.2. Report Methodology

21. DelveInsight Capabilities

22. Disclaimer

23. About DelveInsight

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Ankit Nigam
Email: Send Email
Phone: +19193216187
Address:304 S. Jones Blvd #2432
City: Albany
State: New York
Country: United States
Website: https://www.delveinsight.com/report-store/meningioma-market?utm_source=Pressrelease&utm_medium=Pressrelease&utm_campaign=Pressrelease